Sigmapharm FDA Thursday, December 10, 2020 0.00 Neutral

FDA Approves ASENAPINE — Sigmapharm Laboratories, LLC

Sigmapharm Laboratories secured FDA approval for its generic, sublingual Asenapine tablets, a development expected to increase generic market penetration and exert competitive pricing pressure on the branded antipsychotic.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day